

ANTIMICROBIAL SUSCEPTIBILITY PROFILE (01/01/2023 to 12/31/2023)
MedStar Montgomery Hospital

Gram Negative Organisms	Number of Isolates	Percent Susceptible																	
		Amikacin***	Ampicillin	Ampicillin/sulbactam	Aztreonam	Cefazolin (Systemic ¹)	Cefazolin (Urine ²)	Cefepime	Ceftazidime	Ceftioxone	Ciprofloxacin	ESBL (Negative)	Gentamicin***	Meropenem	Nitrofurantoin*	Piperacillin/tazobactam	Tetracycline	Tobramycin***	Trimethoprim/Sulfa
<i>Acinetobacter baumannii</i>	30	88	-	50	-	-	-	50	52	31	38	-	45	-	-	-	-	74	-
<i>Enterobacter cloacae</i>	83	99	1	1	86	-	-	87	82	82	75	-	89	100	73	86	68	88	81
<i>Escherichia coli</i>	881	100	46	55	84	61	77	86	83	84	61	85	90	100	97	96	68	89	70
<i>Klebsiella pneumoniae ssp pneumoniae</i>	335	99	0	68	79	68	79	79	79	79	77	79	84	98	93	84	76	83	79
<i>Morganella morganii</i>	39	100	0	36	97	-	-	100	95	95	80	-	90	92	0	95	44	90	72
<i>Proteus mirabilis</i>	165	98	79	84	99	0	83	97	99	93	69	-	96	-	0	99	0	93	80
<i>Pseudomonas aeruginosa</i>	232	100	-	-	69	-	-	84	81	-	70	-	-	88	-	78	-	100	-

Gram Positive Organisms	Number of Isolates	Percent Susceptible														
		Ampicillin	Ceftriaxone (meningitis)	Ceftriaxone (non-meningitis)	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Linezolid	Moxifloxacin	Nitrofurantoin*	Oxacillin	Penicillin (meningitis)	Penicillin (non-meningitis)	Tetracycline	Trimethoprim/Sulfa
<i>Enterococcus faecalis</i>	209	100	-	-	-	100	-	-	100	-	-	-	-	-	-	92
<i>Enterococcus faecium</i>	56	49	-	-	-	97	-	-	84	-	-	-	-	-	-	29
Methicillin resistant <i>Staphylococcus aureus</i> (MRSA)***	100	-	-	-	54	100	84	16	100	-	-	0	-	-	73	79
Methicillin sensitive <i>Staphylococcus aureus</i> (MSSA)	141	-	-	-	82	99	97	66	99	-	-	100	-	-	81	96
<i>Staphylococcus coagulase-negative</i>	347	-	-	-	87	100	96	-	100	-	-	56	-	-	-	100
<i>Streptococcus pneumoniae</i> **	75	-	94	100	84	-	-	60	100	99	-	57	76	88	74	72

Percent Susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient
(-) Drug not tested or drug not indicated
(*) Tested on urine isolate only (**) Due to low incidence, organism incidence consists of totals from MMMC, MFSMC, MGS, MH, and MUMH combined
(***) MRSA rate of the institution was 42% (****) Based on CLSI M100-32nd Ed breakpoints
¹ Cefazolin (systemic), MIC ≤ 2 µg/mL susceptible for infections other than uncomplicated UTIs
² Cefazolin (urine), MIC ≤ 16 µg/mL susceptible